These findings highlight that the differential modulation of CD31+- and CD34+-defined vasculature by PAK1 or PAK4 could be strategically leveraged to optimise chemotherapy and vascular-targeted interventions in pancreatic cancer. Here, PAK1 is linked to pancreatic neoplasm.